7U5.F BIOTON S.A. ZY 20
- Market cap
- EUR 64.9M
- P/E
- -
- P/B
- 0.49x
- ROE
- -4.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7U5.F undervalued?
Graham numberThe Graham number of BIOTON S.A. ZY 20 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOTON S.A. ZY 20 fundamental analysis
No fundamental analysis for BIOTON S.A. ZY 20 yet.
BIOTON S.A. ZY 20 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOTON S.A. ZY 20
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; and oral diabetic drugs.BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
Full company profileBIOTON S.A. ZY 20 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIOTON S.A. ZY 20 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 163M | 233M | 182M | 208M | 283M | 240M |
| Gross Profit | 77.8M | 95.8M | 72.9M | 64.8M | 91.8M | 87.5M |
| Operating Income | 12.6M | 26.0M | -3.06M | -5.12M | 14.5M | -28.4M |
| EBITDA | - | 47.2M | 50.5M | 31.9M | 51.4M | 10.6M |
| Net Income | 2.88M | 1.42M | 2.28M | -15.7M | 3.39M | -28.6M |
| EPS | 0.03 | 0.02 | 0.03 | -0.18 | 0.04 | -0.33 |
| Balance Sheet | ||||||
| Total Assets | 848M | 808M | 822M | 794M | 765M | 772M |
| Total Liabilities | 244M | 204M | 216M | 204M | 171M | 192M |
| Shareholders' Equity | 605M | 604M | 606M | 591M | 594M | 580M |
| Cash & Short-term Investments | 8.86M | 9.34M | 3.88M | 6.96M | 8.28M | 1.29M |
| Cash Flow | ||||||
| Operating Cash Flow | 5.52M | 56.1M | 39.6M | 36.3M | 22.6M | -1.06M |
| Capital Expenditure | 12.9M | 29.6M | 44.2M | 11.2M | 13.1M | 19.2M |
| Free Cash Flow | -7.37M | 26.5M | -4.54M | 25.1M | 9.56M | -20.2M |
| Ratios | ||||||
| ROE | 0.5% | 0.2% | 0.4% | -2.7% | 0.6% | -4.9% |
| ROA | 0.3% | 0.2% | 0.3% | -2.0% | 0.4% | -3.7% |
| Net Profit Margin | 1.8% | 0.6% | 1.3% | -7.5% | 1.2% | -11.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIOTON S.A. ZY 20 dividends
BIOTON S.A. ZY 20 has not paid dividends in the last 8 fiscal years.
Who owns BIOTON S.A. ZY 20
- Insiders 54.85%
- Institutions 0.28%
- Public & others 44.87%
- Shares outstanding 85.9M
- Free float 38.8M
BIOTON S.A. ZY 20 company profile
- Company name
- BIOTON S.A. ZY 20
- Ticker
- 7U5.F
- ISIN
- PLBIOTN00029
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 361
- Fiscal year end
- December
- Address
- ul. Poznanska 12, Ozarów Mazowiecki, Poland, 05-850
- Phone
- 48 22 721 4000
- Website
- bioton.pl
About BIOTON S.A. ZY 20
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; and oral diabetic drugs.BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
BIOTON S.A. ZY 20 management
9- Mr. Jeremy LaundersCEO & President of the Management Board
- Ms. Anna GrabowskaFinance Manager
- Mr. Michal DeptuchOperations Director
- Mr. Romuald Apollo HarwasMember of Management Board
- Renata ProkopczykChief Accountant
- Mr. Dariusz GurtowskiDirector of Science & Technology
- Ms. Kamila MusnickaDirector of Legal Department
- Ms. Ewelina RomanskaDirector of HR & Communication
- Mr. Mateusz Patryk KoseckiHead of Biolek Business Unit & CEO of Biolek Sp. Z O.O. · born 1975